Karus secures investment to develop cancer drugs

Published: 16-Jan-2009
Sustainability Research & Development

Karus Therapeutics, a pharmaceutical spin-out from the University of Southampton, has secured funding of


Karus Therapeutics, a pharmaceutical spin-out from the University of Southampton, has secured funding of £900,000 to develop new drugs to treat cancer and inflammatory diseases.

The investment will be used to advance the development of new drugs to treat diseases such as rheumatoid arthritis and psoriasis, and includes medicines based on Karus’s HDAC inhibitor (HDI) platform.

Karus’s HDIs are expected to offer patients the promise of a potent and safe treatment.

Investors include IP Venture Fund, Esperante Ventures, Drummond Paris and a number of Business Angels.

Simon Kerry, Karus Therapeutics’ ceo, said: ‘To have secured this investment in the current economic climate is a tremendous achievement. We have made strong progress on a relatively modest investment to date and aim to use these new funds to create shareholder value through our development programmes in cancer and inflammation.’

Karus was created in 2005 to develop a new family of highly potent, HDAC inhibitors identified by the University of Southampton and Cancer Research UK.

Karus is currently based at the SETsquared Business Incubation Centre at the University of Southampton.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Subscribe now